Bridge Bio­ther­a­peu­tic­s' ul­cer­a­tive col­i­tis drug fails Phase II tri­al; biotech plans to push for­ward

South Ko­re­an biotech Bridge Bio­ther­a­peu­tics an­nounced Mon­day that its mid-stage tri­al for an ul­cer­a­tive col­i­tis drug failed.

The biotech said that its drug can­di­date BBT-401 did not im­prove clin­i­cal re­sponse com­pared to place­bo — mea­sured by a de­crease of ≥3 points and a ≥30% im­prove­ment in Mayo score, which mea­sures in­flam­ma­tion in ul­cer­a­tive col­i­tis.

While the tri­al en­rolled 38 pa­tients in to­tal, on­ly 33 were evalu­able, with 11 in each group. In the place­bo group, 7 of 11 pa­tients (63.6%) met the clin­i­cal re­sponse bar at day 57. In both treat­ment groups — once-dai­ly and twice-dai­ly — 6 of 11 (54.5%) did.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER